Dapivirine (TMC120) 是二芳基嘧啶 (DAPY) 的原型，是具有口服活性的非核苷類逆轉(zhuǎn)錄酶抑制劑 (NRTI)。Dapivirine (TMC120) 可直接與 HIV 的逆轉(zhuǎn)錄酶結(jié)合。Dapivirine (TMC120)調(diào)節(jié)自噬并誘導(dǎo) Akt、Bad 和 SAPK/JNK 的激活。

Dapivirine (4-64 μM, 24, 48, 72, 96 and 120 hours) inhibits proliferation of glioma cells and induces apoptosis (16 μM, 12-48 h)[1].
Dapivirine (8 and 16 μM, 12 h) enhances invasion of glioma cells[1].
Dapivirine (16 μM, 12 h, 24 h and 48 h) promotes autophagy in U87 cells[1].
Dapivirine (TMC120-R147681) apparently blocks infection in the primary cultures at a 10 nM concentration, but secondary cultures revealed that a 100 nM concentration was needed to completely prevent proviral integration[3].

Dapivirine (16 mg/kg, once every 3 days for 12 days) exhibits potent antitumor activity in human glioblastoma models in mice[1].
Dapivirine has been shown to have a half-life in the range of 65 to 90 h[4].